Moderna's mRNA Flu Vaccine Shows Significant Improvement in Efficacy

Moderna announced that its mRNA flu vaccine, mRNA-1010, demonstrated 27% greater efficacy in preventing influenza infections than a standard flu shot in Phase 3 clinical trials. The trial involved nearly 41,000 participants aged 50 and older. mRNA-1010 showed an overall 26.6% higher efficacy than the standard vaccine, rising to 27.4% in participants aged 65 and older. This is particularly encouraging given the severity of the 2024-2025 flu season. Moderna's CEO stated that the mRNA flu vaccine has the potential to more precisely match circulating strains, enable rapid response to future pandemics, and pave the way for COVID-19 combination vaccines.